आईएसएसएन: 2332-0877

संक्रामक रोग और थेरेपी जर्नल

खुला एक्सेस

हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।

ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं

में अनुक्रमित
  • सूचकांक कॉपरनिकस
  • गूगल ज्ञानी
  • जे गेट खोलो
  • RefSeek
  • हमदर्द विश्वविद्यालय
  • ईबीएससीओ एज़
  • ओसीएलसी- वर्ल्डकैट
  • पबलोन्स
  • यूरो पब
  • आईसीएमजेई
इस पृष्ठ को साझा करें

अमूर्त

Intramuscular Ceftriaxone with Oral Antibiotic Therapy in the Treatment of Outpatient Cellulitis

Meghan Theofiles, Jasmine R Marcelin, Lori Herges, Alberto Marcelin, Julie Maxson and Kurt B Angstman

Purpose: Oral antibiotics are the treatment of choice for outpatient cellulitis; however, intramuscular (IM) antibiotics are frequently used in addition to oral antibiotics in the clinic setting. This study compared outcomes among patients with cellulitis who were administered IM ceftriaxone in addition to oral antibiotics versus those who received oral antibiotics alone.

Methods: This study was a retrospective chart review of 982 adult primary care patients designed to evaluate rates of treatment failure of outpatient cellulitis among patients who received IM ceftriaxone and oral antibiotics versus oral antibiotics alone. Treatment failure was defined as: 1) hospital admission for intravenous (IV) antibiotics within 30 days of diagnosis, 2) prolonged antibiotic course, or 3) requiring a different antibiotic after initial antibiotic course.

Results: Of the 982 patients in the study cohort, 104 (10.6%) received IM ceftriaxone in addition to oral antibiotics while 878 (89.4%) did not. In the IM ceftriaxone group, hospitalization within 30 days was seen in 10.6% vs. 4.2% of the oral treatment only group (p=0.004). Initial outpatient use of IM ceftriaxone was associated with a 3.031 (95% CI 1.928-4.765, p<0.001) increased adjusted odds ratio for treatment failure. Age, gender, race, the use of tobacco, and diagnosis of diabetes mellitus were not associated with adverse outcomes when controlling for all other variables.

Conclusions: The patients who received an initial dose of IM ceftriaxone in addition to oral antibiotics were more likely to experience treatment failure than the non-ceftriaxone cohort. With increasing emergence of antibiotic resistant organisms, antibiotic prescribing practices must be reviewed to ensure efficacy and minimize risks associated with unnecessary antibiotic exposure.